Evamist Shortage Update: What Patients Need to Know in 2026

Patients and providers searching for Evamist (estradiol transdermal spray) in 2026 are finding it harder to locate than expected. While Evamist is not on the FDA's formal drug shortage list, real-world availability challenges are affecting many patients. Here's everything you need to know about the current situation and your best options.

Current Evamist Availability Status (2026)

As of 2026, Evamist is not listed on the FDA's official drug shortage database. Padagis, the manufacturer, has not announced any production or distribution problems since relaunching the product in 2022. However, Evamist has never been a high-volume pharmacy staple — not every pharmacy carries it, and those that do may stock only small quantities.

The practical result: patients are being told "out of stock" or "we don't carry that" at pharmacies that either never ordered it or have temporarily run through their supply. This is a distribution and stocking issue, not a manufacturing shortage.

What's Driving the Difficulty Finding Evamist in 2026?

Several factors are converging to make Evamist harder to find:

Estradiol patch shortage spilling over: Millions of patients who use estradiol patches (Vivelle-Dot, Climara, Lyllana) have been redirected to alternative transdermal products — and Evamist is a primary recommendation. This demand surge hit a product with historically limited pharmacy inventory.

FDA black box warning removal (late 2025): The FDA removed the long-standing black box warning from bioidentical estradiol products in late 2025. This decision, based on updated safety evidence, led to a significant increase in new HRT prescriptions across all estrogen formulations — including Evamist.

No generic version: Evamist is brand-name only. There is no generic estradiol transdermal spray that pharmacies can substitute when Evamist supply is thin. Every prescription requires Padagis-manufactured product.

Limited pharmacy stocking history: Evamist was off the market for years before its 2022 relaunch. Many pharmacies never added it back to their standard formulary, so they simply don't order it regularly.

What Has Changed Since 2022?

Evamist was relaunched by Padagis in 2022, nearly a decade after being discontinued by its previous manufacturer. The 2022 relaunch was welcomed by the HRT community as a unique delivery format with no generic competition. For two years, availability was reasonable — the patient population was small and stable. But the 2025-2026 surge in HRT demand has changed the calculus significantly.

Is This Shortage Likely to Resolve?

Because Evamist is not experiencing a manufacturing failure, availability should stabilize as pharmacies recognize increased demand and adjust their ordering. However, the broader HRT demand wave — driven by the patch shortage and the black box removal — is unlikely to subside quickly. Patients should plan to actively manage their Evamist refills for the foreseeable future.

What Should Patients Do Right Now?

Use medfinder to check which pharmacies near you have Evamist in stock

Try independent pharmacies — they often have more flexible ordering than chains

Ask your pharmacy to place a special order for Evamist if they don't have it in stock

Explore mail-order pharmacy options (Amazon Pharmacy, Express Scripts, Optum Rx)

If Evamist remains unavailable, ask your prescriber about alternatives to Evamist — such as EstroGel, Divigel, or oral estradiol

Don't Let a Supply Issue Interrupt Your HRT

Stopping or skipping estrogen therapy without guidance from your provider can cause vasomotor symptoms to return quickly and may have other health implications. If you're having trouble finding Evamist, reach out to your prescriber early — don't wait until you've run out. There are safe, effective options to bridge the gap if needed.